Portfolio
Portfolio Companies
410 Medical
410 Medical
410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. 410 Medical’s first product, LifeFlow PLUS, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening illnesses such as sepsis and shock. LifeFlow PLUS is a hand-operated rapid infuser that allows clinicians to rapidly deliver blood, blood components, crystalloids or colloid fluids to critically ill patients requiring volume resuscitation. LifeFlow was cleared by the U.S. Food and Drug Administration (FDA) for human use in 2016. For more information, visit 410Medical.com
B-Secur
B-Secur
B-Secur is on a mission to save and improve millions of lives each year by advancing heart health technology that brings greater clarity to electrocardiogram (ECG) interpretation with better data and deeper insights. Their technology uses a suite of powerful ECG algorithms and analytics that enhances signal clarity, reduces signal noise and delivers FDA-cleared health data with actionable wellness insights. They partner with world-leading medical and consumer devices and platforms to reduce time to market and enhance the next generation of cardiac monitoring. Learn more at B-Secur.com
Endogenex
Endogenex
The company's technology offers a medical device that provides diabetic patients with a way to regain control of their blood glucose levels, enabling patients to improve glycemic control in patients with type 2 diabetes (T2D). The company has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa. Learn more at Endogenex.com
EvidenceCare
EvidenceCare
EvidenceCare is a platform that links to a clinician's electronic health record (EHR) workflow and delivers personalized, interactive, curated guidance straight into the treatment process, enabling clinicians to give evidence-based care with quantifiable results. Using clinical decision support system (CDSS) technology, variation is decreased and the proper care criteria are documented during usage/admission decisions, thereby enabling healthcare systems to make sure that quality and safety improve, liability is minimized, and efficiency is improved while increasing revenue. Learn more at Evidence.care
Quanta DT
Quanta DT
Quanta Dialysis Technologies Ltd. is a medical technology leader with a vision for more flexible and accessible dialysis care. Quanta’s portable hemodialysis system SC+ is the only next-generation system that delivers the performance and dose equivalence of larger, traditional dialysis systems — with on-demand dialysate production and high dialysate flow rates — while also offering the portability, digital connectivity and ease-of-use of a next-generation dialysis device. Learn more at Quantadt.com
Sensydia
Sensydia
Sensydia's mission is to advance cardiovascular and critical patient care by overcoming today's limitations in acquiring vital hemodynamic measures. The Sensydia Cardiac Performance System™ (CPS) is designed to deliver accuracy equivalent to gold-standard measures on a single, automated and noninvasive platform. The Sensydia team has invested nearly a decade in research and development to create this highly differentiated platform. The CPS platform enables the rapid assessment of key metrics such as ejection fraction (EF) (FDA approved 2018), cardiac output (CO) and pulmonary artery pressure (PAP). With further development, the measurement capabilities of the CPS also will be used to automatically detect cardiac abnormalities and rapidly screen for prevalent heart conditions at the point of care. Learn more at Sensydia.com
Vergent Bioscience
Vergent Bioscience
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real time, ensuring all tumor tissue is removed. The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. For more information, visit VergentBio.com
Vesalio
Vesalio
Vesalio is dedicated to advancing the care of patients suffering from vascular occlusion by providing physicians superior technology designed to improve clinical outcomes. Vesalio’s proprietary NeVa™ platform is designed to consistently achieve first-pass recanalization in acute ischemic stroke by effectively removing all types of neurovascular clots from a patient’s anatomy. For more information, visit Vesalio.com
Biostable Science & Engineering
Biostable Science & Engineering
BioStable Science and Engineering is a cardiovascular device company focused on developing technologies that provide an alternative to heart valve replacement for patients with aortic valve disease. BioStable’s HAART Aortic Valve Repair Technologies have been developed to simplify and standardize valve repair for aortic valve insufficiency, expanding treatment options for many patients. Learn more at Biostable-s-e.com
Process Bolt
Process Bolt
ProcessBolt is an operator of a vendor risk assessment platform created to simplify and accelerate the enterprise risk management process. ProcessBolt’s AI-Assisted Third-Party Risk Management Solution is a cutting-edge platform designed to revolutionize how organizations manage and mitigate risks associated with their third-party vendors and partners. Leveraging advanced artificial intelligence technology, ProcessBolt equips organizations to assess and mitigate third-party risks with unparalleled efficiency. Learn more at processbolt.com.
Gauss Surgical (exited)
Gauss Surgical (exited)
Gauss Surgical provides insights that transform patient care. Gauss Surgical's real-time blood monitoring solutions provide an accurate and objective estimation of blood loss — helping to optimize transfusion decisions, recognize hemorrhage status and improve patient outcomes. Their signature Triton OR product captures blood loss collected by surgical sponges and suction canisters while integrating into operating room workflow, providing superior accuracy when compared to visual estimation and gravimetric methods. Learn more at GaussSurgical.com Exit Fall 2021
Phynd (exited)
Phynd (exited)
Phynd offers healthcare systems a solution suite of software as a service (SaaS) applications and professional services that securely gathers, manages and shares high quality provider data to improve clinical communications, revenue cycle, provider search, operational productivity and risk management. Phynd is the first healthcare IT company to offer a secure cloud-based platform, SaaS applications and professional services that combine external and internal data sources to create unique composite provider profiles crucial for healthcare business processes and patient care. Learn more at Phynd.com Exit Summer 2021
Health Catalyst (exited)
Health Catalyst (exited)
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations, committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Their enterprise data warehouse (EDW) and analytics platform helps improve quality, add efficiency and lower costs in support of more than 65 million patients for organizations ranging from the largest U.S. health system to forward-thinking physician practices. Learn more at HealthCatalyst.com Exit Fall 2019
Rediscovery Life Sciences (exited)
Rediscovery Life Sciences (exited)
reDiscovery Life Sciences (RLS) is a biopharma company located in Cambridge, MA who specializes in developing new medicines through drug repurposing. Compared with traditional drug development, repurposing can produce results more efficiently and with higher success rates. RLS has advantaged access to the repurposing innovation ecosystem through its proprietary Systems Pharmacology Insights Engine (SPIE). RLS is currently in development of compound RLS-003, a drug to treat Acute Kidney Injury (AKI), which will complete Phase II efficacy studies in early 2023. Learn more at rediscoveryls.com
Bio 54 (exited)
Bio 54 (exited)
Bio 54 is the first portfolio company of 501 Ventures. It recently closed on its Series A to advance the IP for a drug/device combination product to treat excessive bleeding in patients on anticoagulants/anti-platelet therapies. Founded by a group of entrepreneurs and Life Science executives, 501 Ventures seeks to bring efficiency to drug development by sharing the management team across multiple portfolio companies as well as conducting the majority of clinical work in house. Our primary focus is non-oncology, small molecule products that are between 18 months to the clinic through Phase 2.
Biostable Science & Engineering (exited)
Biostable Science & Engineering (exited)
BioStable Science & Engineering is a cardiovascular device company focused on developing technologies that provide an alternative to heart valve replacement for patients with aortic valve disease. BioStable’s HAART Aortic Valve Repair Technologies have been developed to simplify and standardize valve repair for aortic valve insufficiency, expanding treatment options for many patients. Learn more at Biostable-s-e.com